Isabel Coma-Canella
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Isabel Coma-Canella has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
Amelia Velasco
2 shared publications- María José García-Velloso
Department of Nuclear Medicine, Clínica Universidad de Navarra, Pamplona, Spain
2 shared publications Sara Castano
Department of Cardiology, Clínica Universitaria, Facultad de Medicina, Universidad de Navarra, Avenida de Pio XII, 36. 31008, Pamplona, Spain
2 shared publicationsAlfonso Macías
Servicio de Cardiología, Clínica Universitaria, Facultad de Medicina, Universidad de Navarra, Pamplona, Spain
1 shared publication- Alfonso Macías
Department of Cardiology and Cardiovascular Surgery , University Clinic, School of Medicine, University of Navarra , Pamplona , Spain
1 shared publication Alfonso Sánchez Ibarrola
Servicio de Inmunología, Clínica Universitaria, Facultad de Medicina, Universidad de Navarra, Pamplona. Spain
1 shared publication
Latest Publications
- Open Access
- 1 January 2013
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 12 (1) , 143
The activity of circulating dipeptidyl peptidase-4 is associated with subclinical left ventricular dysfunction in patients with type 2 diabetes mellitus
Patients with type 2 diabetes mellitus (T2DM) present subclinical left ventricular systolic and/or diastolic dysfunction (LVD). Dipeptidyl peptidase-4 (DPP4) inactivates peptides that possess cardioprotective actions. Our aim was to analyze whether the activity of circulating DPP4 is associated with echocardiographically defined LVD in asymptomatic patients with T2DM.
- 1 January 2013
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 12 (1) , 143
Open AccessThe activity of circulating dipeptidyl peptidase-4 is associated with subclinical left ventricular dysfunction in patients with type 2 diabetes mellitus
Patients with type 2 diabetes mellitus (T2DM) present subclinical left ventricular systolic and/or diastolic dysfunction (LVD). Dipeptidyl peptidase-4 (DPP4) inactivates peptides that possess cardioprotective actions. Our aim was to analyze whether the activity of circulating DPP4 is associated with echocardiographically defined LVD in asymptomatic patients with T2DM.
- 1 December 2007
- Published by Bentham Science Publishers Ltd. in Cardiovascular & Hematological Disorders-Drug Targets
- Vol. 7 (4) , 274-287
Variability in Individual Responsiveness to Aspirin: Clinical Implications and Treatment
Abstract: Aspirin protects from cardiovascular events because of its antiaggregant effect. The occurrence of new events in patients who take aspirin has been called clinical aspirin resistance. Many authors believe that aspirin resistance must be detected by biochemical tests, although there is no agreement on which is the best. Nor is there agreement on the term aspirin resistance. Tests used in research laboratories are aggregometry (turbidometric and impedance), tests based on activation- dependent changes in platelet surface, and tests based on activation-dependent release from platelets. Point-ofcare tests are PFA-100, IMPACT and VerifyNow, which can detect platelet dysfunction that may be due to aspirin effect, but their use for this purpose is not yet recommended. Aspirin response may be modified by different factors: patients compliance, dose, smoking, hyperlipidemia, hyperglucemia, acute coronary syndrome, percutaneous revascularization, recent stroke, extracorporeal circulation, heart failure, exercise, circadian rhythm, absorption, concomitant medications, polymorphisms. Patients with aspirin resistance may have an increased risk of cardiovascular events, and possible therapeutic options are to increase the dosage, to replace aspirin with another antiaggregant drug or to add another drug. In conclusion, there are many reasons that explain the variability in individual responsiveness to aspirin. The term resistance is probably not exact in describing this phenomenon.
- 1 December 2007
- Published by Bentham Science Publishers Ltd. in Cardiovascular & Hematological Disorders-Drug Targets
- Vol. 7 (4) , 274-287
Variability in Individual Responsiveness to Aspirin: Clinical Implications and Treatment
Abstract: Aspirin protects from cardiovascular events because of its antiaggregant effect. The occurrence of new events in patients who take aspirin has been called clinical aspirin resistance. Many authors believe that aspirin resistance must be detected by biochemical tests, although there is no agreement on which is the best. Nor is there agreement on the term aspirin resistance. Tests used in research laboratories are aggregometry (turbidometric and impedance), tests based on activation- dependent changes in platelet surface, and tests based on activation-dependent release from platelets. Point-ofcare tests are PFA-100, IMPACT and VerifyNow, which can detect platelet dysfunction that may be due to aspirin effect, but their use for this purpose is not yet recommended. Aspirin response may be modified by different factors: patients compliance, dose, smoking, hyperlipidemia, hyperglucemia, acute coronary syndrome, percutaneous revascularization, recent stroke, extracorporeal circulation, heart failure, exercise, circadian rhythm, absorption, concomitant medications, polymorphisms. Patients with aspirin resistance may have an increased risk of cardiovascular events, and possible therapeutic options are to increase the dosage, to replace aspirin with another antiaggregant drug or to add another drug. In conclusion, there are many reasons that explain the variability in individual responsiveness to aspirin. The term resistance is probably not exact in describing this phenomenon.
- 8 January 2007
- Published by Elsevier in International Journal of Cardiology
- Vol. 114 (2) , 251
Ergonovine test for coronary artery spasm
- 8 January 2007
- Published by Elsevier in International Journal of Cardiology
- Vol. 114 (2) , 251
Ergonovine test for coronary artery spasm
- 1 June 2006
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 13 (3) , 316-323
Myocardial perfusion imaging with adenosine triphosphate predicts the rate of cardiovascular events
- 1 June 2006
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 13 (3) , 316-323
Myocardial perfusion imaging with adenosine triphosphate predicts the rate of cardiovascular events
- 1 March 2006
- Published by Elsevier in Revista Española de Cardiología (English Edition)
- Vol. 59 (3) , 189-92
[Relationship between mortality due to acute myocardial infarction and adherence to clinical guidelines].
- 1 March 2006
- Published by Elsevier in Revista Española de Cardiología (English Edition)
- Vol. 59 (3) , 189-92
[Relationship between mortality due to acute myocardial infarction and adherence to clinical guidelines].
- 1 February 2006
- Published by Elsevier in International Journal of Cardiology
- Vol. 107 (2) , 200-206
Ergonovine test in angina with normal coronary arteries. Is it worth doing it?
- 1 February 2006
- Published by Elsevier in International Journal of Cardiology
- Vol. 107 (2) , 200-206
Ergonovine test in angina with normal coronary arteries. Is it worth doing it?
- 13 January 2006
- Vol. 49 (3) , 41-7
[Heart failure. Current pharmacologic treatment].
Treatment of heart failure (HF) has changed in recent years, despite the paucity of new approved drugs. Current treatment is directed not only towards improving symptoms, but also to preventing the development from asymptomatic systolic dysfunction to symptomatic heart failure, to preventing cardiac remodelling, renal dysfunction and to reducing mortality. The main families of drugs currently used are: cardiac glycosides, diuretics, angiotensin-converting enzyme inhibitors (ACEI), beta-blocking drugs (BB), angiotensin-II receptor blockers (ARB) and aldosterone receptor antagonists. The combination isosorbide dinitrate + hydralazine is hardly used due to its side effects and none of the new positive inotropic drugs has been approved in chronic HF, because all of them increase mortality. Levosimendan is a new positive inotropic agent approved for acute HF by an intravenous route, with a favourable effect on prognosis vs placebo and vs dobutamine (which worsens the prognosis). The approved oral drugs can be given at the same time if the patient tolerates them, because their beneficial effect is additive. Mortality in two years in mild to moderate HF is 34% with glycosides + diuretics. It falls to 22% when an ACEI is added, to 14% when a BB is added and to 10% when an aldosterone antagonist is added. ARB can be given instead of an ACEI or be added to the other drugs.
- 13 January 2006
- Vol. 49 (3) , 41-7
[Heart failure. Current pharmacologic treatment].
Treatment of heart failure (HF) has changed in recent years, despite the paucity of new approved drugs. Current treatment is directed not only towards improving symptoms, but also to preventing the development from asymptomatic systolic dysfunction to symptomatic heart failure, to preventing cardiac remodelling, renal dysfunction and to reducing mortality. The main families of drugs currently used are: cardiac glycosides, diuretics, angiotensin-converting enzyme inhibitors (ACEI), beta-blocking drugs (BB), angiotensin-II receptor blockers (ARB) and aldosterone receptor antagonists. The combination isosorbide dinitrate + hydralazine is hardly used due to its side effects and none of the new positive inotropic drugs has been approved in chronic HF, because all of them increase mortality. Levosimendan is a new positive inotropic agent approved for acute HF by an intravenous route, with a favourable effect on prognosis vs placebo and vs dobutamine (which worsens the prognosis). The approved oral drugs can be given at the same time if the patient tolerates them, because their beneficial effect is additive. Mortality in two years in mild to moderate HF is 34% with glycosides + diuretics. It falls to 22% when an ACEI is added, to 14% when a BB is added and to 10% when an aldosterone antagonist is added. ARB can be given instead of an ACEI or be added to the other drugs.
- 1 November 2005
- Published by Elsevier in Revista Española de Cardiología (English Edition)
- Vol. 58 (11) , 1273-1277
Neurohormones and Cytokines in Heart Failure. Correlation With Coronary Flow Reserve
- 1 November 2005
- Published by Elsevier in Revista Española de Cardiología (English Edition)
- Vol. 58 (11) , 1273-1277
Neurohormones and Cytokines in Heart Failure. Correlation With Coronary Flow Reserve
- 1 May 2005
- Published by Elsevier in International Journal of Cardiology
- Vol. 101 (1) , 71-76
Prevalence of aspirin resistance measured by PFA-100
- 1 May 2005
- Published by Elsevier in International Journal of Cardiology
- Vol. 101 (1) , 71-76
Prevalence of aspirin resistance measured by PFA-100
- 1 January 2002
- Published by Elsevier in Revista Espanola de Cardiologia
- Vol. 55 (6) , 568-70
Dobutamina en lugar de ergometría para detectar enfermedad coronaria. ¿Es suficiente la información electrocardiográfica?
- 1 January 2002
- Published by Elsevier in Revista Espanola de Cardiologia
- Vol. 55 (6) , 568-70
Dobutamina en lugar de ergometría para detectar enfermedad coronaria. ¿Es suficiente la información electrocardiográfica?